• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: C.R. BARD, INC. (COVINGTON) -1018233; PELVILACE® BIOURETHRAL SUPPORT SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

C.R. BARD, INC. (COVINGTON) -1018233; PELVILACE® BIOURETHRAL SUPPORT SYSTEM Back to Search Results
Device Problems Migration or Expulsion of Device (1395); Material Protrusion/Extrusion (2979)
Patient Problems Abdominal Pain (1685); Erosion (1750); Cyst(s) (1800); Fistula (1862); Hemorrhage/Bleeding (1888); Incontinence (1928); Inflammation (1932); Pain (1994); Perforation (2001); Urinary Tract Infection (2120); Weakness (2145); Dizziness (2194); Prolapse (2475); Hematuria (2558); Constipation (3274)
Event Type  Injury  
Manufacturer Narrative
The sample was not returned.The finished product met all specifications prior to being released for general distribution.The instructions for use which accompanies all devices currently addresses potential risks associated with surgically implanted materials.The instructions for use states in the adverse events: "the pelvilace¿ biourethral support system is for single-patient use only and is to be implanted surgically.Do not use the pelvilace¿ biourethral support system if the integrity of the packaging appears compromised.The pelvilace¿ biourethral support system pelvicol® implant should be hydrated or moist when the package is opened.Dehydrated or dry tissue should not be implanted.Postoperative retropubic bleeding may occur in some patients and must be controlled prior to patient release.The pelvilace¿ biourethral support system procedure requires diligent attention to anatomical structure and care to avoid puncture of large vessels, nerves, bladder, and bowel, during needle passage.Proper placement of the pelvilace¿ biourethral support system at mid-urethra requires that the tissue lie flat with minimal or no tension under the urethra.The pelvilace¿ biourethral support system is intended as a single-use, disposable device.Do not resterilize any portion of the pelvilace¿ biourethral support system.Patients should be advised that pregnancy following an pelvilace¿ biourethral support system procedure may negatively affect the success of the previous procedure and incontinence may reoccur.The safety and effectiveness of pelvilace¿ biourethral support system has not been established for the treatment of stress urinary incontinence in males and children under the age of 18.¿.
 
Event Description
The patient's attorney alleged a deficiency against the device.It was reported by the patient¿s attorney that as a result of having the product implanted, the patient has experienced hemorrhoids, constipation, urinary tract infection, cystitis (inflammation), urinary incontinence, blood, nitrates, many bacteria, leukocytes, white blood cells, red blood cells in urine (hematuria and bacterial infection), abdominal pain, anemia, low red blood cells, hemoglobin and hematocrit, high eosinophils, escherichia coli in urine, rectal bleed secondary to internal hemorrhoids (blood loss), dizziness, difficulty with bowel movement, blood while straining, weakness, constipation and moderate fecal retention, tiny calculus mid pole of the left kidney, lower pole of right kidney, small left renal cyst, low potassium (electrolyte imbalance), retention, enterocele, colovesical fistula, recurrence, pain, unspecified urinary problems, unspecified neuromuscular problems, organ perforation, pelvic pain, erosion, vaginal bleeding, unspecified bowel problems, unspecified perforation, recurrence, pelvic organ prolapse, stress migration and extrusion, cystocele, foreign body in patient, urethra disorder, female genital prolapse, additional surgical and nonsurgical intervention.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Type of Device
PELVILACE® BIOURETHRAL SUPPORT SYSTEM
Manufacturer (Section D)
C.R. BARD, INC. (COVINGTON) -1018233
8195 industrial blvd
covington GA 30014
Manufacturer (Section G)
C.R. BARD, INC. (COVINGTON) -1018233
8195 industrial blvd
covington GA 30014
Manufacturer Contact
angela robinson
8195 industrial blvd
covington, GA 30014
7707846100
MDR Report Key8680472
MDR Text Key147448241
Report Number1018233-2019-02982
Device Sequence Number1
Product Code PAG
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K042949
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type other
Reporter Occupation Non-Healthcare Professional
Type of Report Initial
Report Date 06/07/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received06/07/2019
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Was the Report Sent to FDA? No
Device Age3 MO
Event Location Hospital
Date Manufacturer Received05/15/2019
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured08/16/2006
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
-
-